A National Shortage Forces a Rethink on Diabetes Insipidus Treatment
A recent retrospective study published in *Clinical Endocrinology* evaluated the clinical outcomes of patients with arginine vasopressin deficiency (AVP-D) who were urgently switched from intranasal to oral desmopressin due to a national supply suspension. The research, conducted at a UK tertiary centre, analyzed data from 42 patients and was paralleled by a national patient impact report. Findings revealed significant variability in effective conversion ratios, with over half of the patients initially switched at a 1:10 ratio experiencing symptomatic recurrence. The transition resulted in a substantial clinical burden, including numerous patient calls, additional blood tests, and one hospitalization, highlighting the challenges of managing a chronic endocrine condition during a drug shortage.
Study Significance: For gastroenterologists and hepatologists managing complex fluid and electrolyte imbalances, particularly in patients with cirrhosis or those undergoing large-volume paracentesis, this study underscores the critical importance of precise hormone replacement. It demonstrates how supply-chain disruptions can directly impact patient outcomes and increase healthcare utilization, a scenario directly applicable to shortages of other essential gastroenterology medications. The findings advocate for the development of standardized, flexible protocols for drug substitution that prioritize patient safety while minimizing the risk of complications like hyponatraemia, a common concern in both endocrinology and hepatology practice.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
